Cancer Research Institute (CRI) shared a post on LinkedIn:
“Researchers including CRI Technology Impact Investigator Dr. Ido Amit at Weizmann Institute of Science developed a novel cancer immunotherapy called MiTEs that targets two types of immune cells simultaneously to overcome current treatment limitations.
Investigators designed these engineered proteins to both disable tumor-protecting macrophages and activate cancer-killing T cells and NK cells.
The innovation lies in MiTEs’ built-in safety switch: they carry a masked version of IL-2 that only becomes active inside tumors, where specific enzymes unlock it, preventing dangerous side effects in healthy tissues.
In preclinical models, MiTEs demonstrated the ability to reprogram the entire tumor immune environment, creating a coordinated attack that current single-target therapies cannot achieve.
This dual-action approach could transform the treatment of solid tumors by addressing their complex defense mechanisms, while keeping patients safe from systemic toxicity.”
Title: Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy
Authors: Michelle von Locquenghien, Pascale Zwicky, Ken Xie, Diego Adhemar Jaitin, Fadi Sheban, Adam Yalin, Florian Uhlitz, Chamutal Gur, Reut Sharet Eshed, Eyal David, Kfir Mazuz, Caroline Jennings Marin, Ankita Sankar, Devin Mediratta, Roberto Avellino, Assaf Weiner, Ido Amit
You can read the full article in Cell by Cell Press.
More posts from Cancer Research Institute (CRI) on OncoDaily.